Lambda Research Newsletter

GLOBAL NEWS

1. Increasing Capital Expenditures seen with bio/pharmaceutical companies

Bio/pharmaceutical companies have increased their annual Capital Expenditure (CapEx) by 6.8% ($35.3 billion) from 2010 to 2015, while the overall revenue growth of the bio/pharmaceutical industry has been just 3.3% during the same period.


The major factor that impedes quicker growth of the contract manufacturing and development industry is captive capacity; and employment of capital towards development of new plant and equipment by bio/pharmaceutical companies is an important factor that indicate the industry's approach towards the make or buy decision.

In the past 5 years, bio/pharma companies have invested about $150 billion for new plant and facilities, as reported by Bio/Pharma CapEx Trends 2016, which was 10 times more than the investment done by CMOs for themselves.

Source: health.economictimes.indiatimes.com

CONTENTS

GLOBAL NEWS

  1. Increasing Capital Expenditures seen with bio/pharmaceutical companies
  2. GMP inspections of APIs: Japan joins international collaboration
  3. New guidelines developed for HER2 testing for gastroesophageal adenocarcinoma
  4. US FDA clears backlog of nearly 4000 excipient formulations in its Inactive Ingredient Database

TECHNOLOGY/ NDDS NEWS

  1. Modified PEG as a new drug delivery technology
  2. Web-based computational tool for cancer treatment optimization
  3. Contact Us:

    Dr. Tausif Monif

    President - Global Operations

    Tausifmonif@lambda-cro.com

    Dr. Mrinal Kammili

    Ex. Director – Global Head, BD

    mrinal@lambda-cro.com

    Disclaimer: “The information compiled and published in this newsletter have been collected from various public domain resources available on web and relevant magazines. The Public Domain information is not confidential and may be freely distributed and copied. However, transmission or reproduction of protected items beyond that allowed by fair use as defined in the copyright laws requires the written permission of the copyright owners, if any. Lambda directly or indirectly shall not be responsible for any legal/ethical litigation claimed by any professional agency / bodies.”